key: cord-0902068-7ld7hyaw authors: Philippens, Ingrid H.C.H.M.; Böszörményi, Kinga P.; Wubben, Jacqueline A.; Fagrouch, Zahra C.; van Driel, Nikki; Mayenburg, Amber Q.; Lozovagia, Diana; Roos, Eva; Schurink, Bernadette; Bugiani, Marianna; Bontrop, Ronald E.; Middeldorp, Jinte; Bogers, Willy M.; de Geus-Oei, Lioe-Fee; Langermans, Jan A.M.; Stammes, Marieke A.; Verstrepen, Babs E.; Verschoor, Ernst J. title: SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques date: 2021-05-05 journal: bioRxiv DOI: 10.1101/2021.02.23.432474 sha: 89a099c930037cec30c6b18cdd313f3e51cf3e29 doc_id: 902068 cord_uid: 7ld7hyaw SARS-CoV-2 may cause acute respiratory disease, but the infection can also initiate neurological symptoms. Here we show that SARS-CoV-2 infection causes brain inflammation in the macaque model. An increased metabolic activity in the pituitary gland of two macaques was observed by longitudinal positron emission tomography-computed tomography (PET-CT). Post-mortem analysis demonstrated infiltration of T-cells and activated microglia in the brain, and viral RNA was detected in brain tissues from one animal. We observed Lewy bodies in brains of all rhesus macaques. These data emphasize the virus’ capability to induce neuropathology in this nonhuman primate model for SARS-CoV-2 infection. As in humans, Lewy body formation is an indication for the development of Parkinson’s disease, this data represents a warning for potential long-term neurological effects after SARS-CoV-2 infection. Teaser SARS-CoV-2 causes brain inflammation and Lewy bodies, a hallmark for Parkinson, after an asymptomatic infection in macaques. Additionally, activation of microglia cells in different areas of the brain, including the olfactory 115 bulb and pituitary gland, was confirmed by Mamu-DR staining (upregulation of MHC class II 116 expression) (Fig. 3A, middle panel) . However, nodule formation, which is a measure for severity 117 of activation, was rarely present (Table 2) . No B-lymphocytic infiltration was found as evidenced 118 by lack of CD20 staining (not shown). Hematoxylin and eosin (HE) staining did not show any 119 abnormalities in the brain tissue of the virus-exposed macaques, including the absence of 120 ischemic/necrotic lesions. For comparison, post-mortem brain tissues from two healthy, age-121 matched macaques of each species were used as controls (Table 1) animals. For cynomolgus macaque C4, an age-dependent factor related to Parkinsonism cannot 132 be excluded as this animal was older (16 years) than the other panel members (5-7 years), but 133 the data from the rhesus macaques provide clear evidence for SARS-CoV-2-driven inflammation 134 in the brain of macaques. In humans, neuropathology has been described in moribund COVID-19 135 patients, but we report of SARS-CoV-2-related brain involvement in macaques without displaying overt clinical signs. In general, macaque models for SARS-CoV-2 infection typically represent mild 137 to moderate COVID-19 symptoms on the CT scan compared to humans (12, 14, 31) . Detection of 138 viral RNA in the brain of an animal demonstrates the virus' neuroinvasive capability. This matches 139 a recent study describing neuroinvasion in mouse brains and in human brain organoids (32). 140 How exactly SARS-CoV-2 caused widespread brain inflammation and induced Lewy body 141 formation remains unknown. Viruses can enter the brain via different pathways. In this study, 142 infiltration of T-cells was found perivascular and in the brain parenchyma, which indicates that 143 the blood-brain barrier integrity may have been disturbed, offering the virus the opportunity to 144 enter the brain. Alternatively, we hypothesize that SARS-CoV-2 gained access to the brain via 145 neuronal pathways, such as the retrograde and anterograde neuronal transport through infected 146 motor or sensory neurons (33), and entered the pituitary gland via binding to the ACE2 receptor 147 protein expressed on its cell surfaces (18, 34). Such neural connection also exists between the 148 olfactory bulb and the nasal mucosa (35), and the loss of taste and smell, a characteristic of 149 COVID-19, can thus be explained by nasal infection and subsequent inflammation in the olfactory 150 bulb. Such a scenario is in line with the finding that in all the SARS-CoV-2-exposed macaques 151 immune system activation in the olfactory bulb was evidenced by the presence of T-cells and/or 152 activated microglia. 153 Neuronal transport can also explain why some COVID-19 patients develop Parkinson's disease-154 like symptoms. Viruses can also, via retrograde transport in parasympathic motor neurons of the 155 nervus vagus to the medulla, pons, and midbrain, reach the substantia nigra in the midbrain (27, 156 36) . Notably, the a-synuclein inclusions were found in the ventral midbrain region of the animals. In humans, these inclusions of accumulated misfolded proteins are associated with Parkinson's 158 disease or Lewy body dementia (37). 159 There is a growing concern that symptomatic COVID-19 patients may suffer from long-term On day 0, all animals were exposed to a dose of 10 5 TCID50 of SARS-CoV-2 (strain 195 BetaCOV/BavPat1/2020), diluted in 5 ml phosphate-buffered saline (PBS). The virus was 196 inoculated via a combination of the intratracheal route (4.5 ml) and intranasal route (0.25 ml per 197 nostril). For the histological examination brains from naive control macaques from the same age 198 were obtained from the BPRC biobank, two cynomolgus, and two rhesus macaques. The slides were deparaffinized by putting them sequentially in xylene, 100% ethanol, 96% 300 ethanol, 70% ethanol, and PBS. Subsequently, an epitope antigen retrieval was executed and the 301 slides were put in a steamer for 1 hour. The cooled down slides were placed in cuvettes and the 302 endogenous peroxidase activity was blocked by the envision kit. The slides were washed and 303 thereafter a blocking step was used consisting of 1% NHS + 1% BSA + 0.2% triton x100 in PBS for 304 10 minutes. Subsequently, the primary antibody was added (diluted in 0.1% BSA/PBS) for 30 305 minutes. Thereafter a washing step was implemented and the EnVision™ polymer/HRP 306 (secondary antibody) was added for 10 minutes. Polymer HRP was added for 10 minutes followed 307 by a washing step. Thereafter DAB+ was added for 15 minutes to visualize the antigen-antibody 308 binding. and E16C, catno. MA1-7403) were validated on formaldehyde-fixed and paraffin-embedded 332 SARS-CoV-2 and mock-infected Vero E6 cells (10), as well as lung tissue sections of human SARS-CoV-2 patients. The clone E16C was superior to B46F and was further used in this study. Antigen 334 retrieval took place with cell conditioning 1 (CC1 , Ventana Medical Systems) (pH 8,5) for 24 335 minutes at 100°C, 1/5.000 diluted. Thereafter, incubation took place with the primary antibody 336 for 48 minutes at 36°C followed by standard Optiview detection/visualization with DAB and 337 Copper. After immunohistochemical staining, the sections were dehydrated with grades of 338 ethanol and cleared with xylene. All sections were mounted with TissueTek® coverslipping film 339 (Sakura Finetek Europe B.V., Alphen aan den Rijn, The Netherlands). 340 Table 2 outlines the presence of 1) T-cells (CD3+ cells) in the brain tissue (intraparenchymal), 585 around blood vessels (perivascular), in group formation (nodules), or in the meninges, 2) activated 586 microglia (Mamu-DR+ cells) in different parts of the brain, the morphology as a measure for the 587 severity of activation (ramified or amoeboid), in group formation (nodules) or in the meninges, 3) 588 a-synuclein/Lewy bodies (a-synuclein + cells with inclusions) in the ventral midbrain region next 589 to the caudate nucleus. The last column shows the absence of most of these markers in the 590 control animals. Study Group of the International Committee on Taxonomy of, The 343 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV 344 and naming it SARS-CoV-2 Neurologic Manifestations of Hospitalized Patients With Coronavirus 347 Disease The emerging spectrum of COVID-19 neurology: clinical, radiological and 357 laboratory findings Neurobiology of COVID-19 Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A 363 Cross-sectional Study A case of probable Parkinson's 366 disease after SARS-CoV-2 infection Coronavirus Disease 2019 and Parkinsonism: A Non-post-encephalitic Case Acute hypokinetic-374 rigid syndrome following SARS-CoV-2 infection Immediate and long-term 376 consequences of COVID-19 infections for the development of neurological disease Viral presence and immunopathology 383 in patients with lethal COVID-19: a prospective autopsy cohort study Does SARS-Cov-2 invade the 386 brain? Translational lessons from animal models Animal 397 models for COVID-19 Comparison of SARS-CoV-2 402 infection in two non-human primate species: rhesus and cynomolgus macaques Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model Time Course of Lung Changes at Chest CT during Recovery from Coronavirus 412 Disease 2019 (COVID-19) Increased 414 (18)F-FDG signal recovery from small physiological structures in digital PET/CT and 415 application to the pituitary gland Comparative test-retest variability of outcome 418 parameters derived from brain [18F]FDG PET studies in non-human primates COVID-19 and the endocrine system: exploring the unexplored COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications Delayed Onset of Central Hypocortisolism in a Patient 425 Recovering From COVID-19 Tissue 427 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in 428 understanding SARS pathogenesis CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 432 Lewy body dementias Parkinson's Disease Dementia and Lewy Body 436 Disease Viral etiology of Parkinson's disease: Focus on influenza A virus The olfactory vector hypothesis of neurodegenerative disease: is it viable Viremic attack explains the dual-hit theory of Parkinson's disease COVID-19 and neurodegeneration: what can we learn 444 from the past? West Nile Virus-446 Induced Neurologic Sequelae-Relationship to Neurodegenerative Cascades and 447 Dementias The 449 Possible Protective Role of alpha-Synuclein Against Severe Acute Respiratory Syndrome 450 Coronavirus 2 Infections in Patients With Parkinson's Disease Responses to acute 461 infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets Neuroinvasion of SARS-CoV-2 in human and mouse brain Viral diseases of the central nervous system Endocrine Significance of SARS-CoV-2's 473 Reliance on ACE2 Olfactory transmucosal SARS-CoV-2 invasion as a 481 port of central nervous system entry in individuals with COVID-19 Parkinson's disease: a dual-hit hypothesis Toxic proteins in neurodegenerative disease The lasting misery of coronavirus long-haulers A longer look at COVID-19 and neuropsychiatric outcomes Virulence and pathogenesis of 493 SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 494 progression Respiratory disease in rhesus 498 macaques inoculated with SARS-CoV-2 Recommendations for Standardizing Thorax PET-CT in Non-Human Primates by Recent Experience from Macaque Studies. 502 Animals Detection of 2019 novel coronavirus 507 (2019-nCoV) by real-time RT-PCR Virological assessment 511 of hospitalized patients with COVID-2019 The Rhesus Monkey Brain: in Stereotaxic 513 We want to thank Francisca van Hassel for assistance with editing of figures, Yolanda Kap 517 for reviewing the manuscript, Wim Vos for the excellent histology, and the Animal Science gland-brain ratio of animal C1 was calculated with both the mean and peak standard uptake value 553 (SUV); for the SUVmean this ratio was 1.9, and for the SUVpeak 1.3. The average values calculated 554 from a group of non-infected control animals (n=6) were 1.1 (std 0.3) for the SUVmean, and 0.6 (std The standardized uptake values (SUVs) of animals C1 and C2 are represented together with the SUVs of six non-infected control rhesus macaques. Of these animals the average and peak uptake are determined for the pituitary gland, and the brain minus the pituitary gland. By dividing these the pituitary gland/brain ratio is calculated. For the SUVmean values above 1.0 are defined as slightly increased (light grey) and increased (dark grey) when equal or above 1.5. For the SUVpeak values above 1.0 are demarcated as slightly increased and above 1.2 as increased.